Volta Medical's AI-powered AF-Xplorer II transforms atrial fibrillation treatment in the U.S.

Volta Medical has launched its AF-Xplorer II system in the U.S., marking a major step in cardiac care. The AI-powered tool aims to simplify real-time assessment of complex atrial fibrillation (AF). Early adoption in Europe has already shown promising results, with improved success rates in treating the condition.

The AF-Xplorer II received CE Mark approval in Europe in January 2025. Since then, its use in clinical practice has led to better outcomes for patients with complex AF. A study from March 2026 at the Universitätsklinikum Hamburg-Eppendorf reported a 25% reduction in recurrence rates, thanks to the system's precise colour mapping and automated cardiac mapping features.

The system introduces several key improvements over its predecessor. These include high-stability analysis, broader catheter compatibility, and seamless integration with the GE HealthCare CardioLab AltiX AI.i recording system. Volta Medical designed the technology to help electrophysiologists perform more efficient and accurate procedures.

Dr. Devi Nair, Director of Cardiac Electrophysiology at St. Bernard's Heart & Vascular Center, has already used the AF-Xplorer II in procedures. She highlighted its potential to enhance outcomes for patients with challenging AF cases. Théophile Mohr Durdez, CEO and co-founder of Volta Medical, described the system as a significant advance in algorithm specificity and interoperability.

The U.S. launch follows successful adoption in Europe, where the AF-Xplorer II has already improved treatment standards. With its AI-driven capabilities, the system is set to provide electrophysiologists with more precise tools for managing complex AF cases. Hospitals and clinics adopting the technology may see reduced recurrence rates and more standardised care.